Dr. Eure on clinical use and reimbursement of UroLift for BPH

iTind is a temporary nitinol device used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia.

The data were presented at the recent American Urological Association Annual Meeting.

"We really aimed to affect 3 different contraindications and instead achieved retirement of the entire policy, which, we think, really opens up this wonderful technology to literally hundreds of thousands more patients across the country," says Arpeet Shah, MD.

“Even though there [are] many therapies that one can do, it's not a sign of anything ominous for most men,” says Kevin T. McVary, MD, FACS.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia in urology.

All patients had prostates greater than 80 mL and had not responded to prior medication therapy.